Phase II Randomized Study of MK‐2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG‐ACRIN E2809)

Authors

B. Carthon
Ron Rodriguez
Michael Carducci
Tina Mayer (ORCID: https://orcid.org/0000-0003-0078-3773)
Glenn X. Liu
Noah Hahn (ORCID: https://orcid.org/0000-0003-2112-9439)
Yuhui Chen (ORCID: https://orcid.org/0000-0003-2936-6690)
Robert S. DiPaola (ORCID: https://orcid.org/0000-0002-5063-7638)
Gary R. Hudes
Hilary Ma (ORCID: https://orcid.org/0000-0001-7596-0100)
Anna C. Ferrari
Emmanuel S. Antonarakis
Elizabeth R. Plimack

Institutions

Rutgers, The State University of New Jersey (US)
Fox Chase Cancer Center (US)
Montefiore Medical Center (US)
The University of Texas MD Anderson Cancer Center (US)
University of Wisconsin–Madison (US)
University of Kentucky (US)
Johns Hopkins University (US)
Emory University (US)
The University of Texas at San Antonio Health Science Center (US)
Dana-Farber Cancer Institute (US)
Rutgers Cancer Institute (US)

Publication Details

Journal: The Prostate
Published: 2026-01-29
DOI: https://doi.org/10.1002/pros.70125
Primary Topic: Prostate Cancer Treatment and Research
Type: article
Field-Weighted Citation Impact: 0.00

Funders

American College of Radiology Imaging Network
ECOG-ACRIN Cancer Research Group
National Institutes of Health
National Cancer Institute

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Phase II Randomized Study of MK‐2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG‐ACRIN E2809)

B. Carthon, Ron Rodriguez, Michael Carducci, Tina Mayer et al.

Jan 29, 2026

The Prostate

Prostate Cancer Treatment and Research

article

Phase II Randomized Study of MK‐2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG‐ACRIN E2809)

B. Carthon, Ron Rodriguez, Michael Carducci, Tina Mayer, Glenn X. Liu, Noah Hahn, Yuhui Chen, Robert S. DiPaola, Gary R. Hudes, Hilary Ma, Anna C. Ferrari, Emmanuel S. Antonarakis, Elizabeth R. Plimack

January 29, 2026article en

Abstract

No abstract available for this paper.

The Prostate

Rutgers, The State University of New Jersey (US), Fox Chase Cancer Center (US), Montefiore Medical Center (US), The University of Texas MD Anderson Cancer Center (US), University of Wisconsin–Madison (US), University of Kentucky (US), Johns Hopkins University (US), Emory University (US), The University of Texas at San Antonio Health Science Center (US), Dana-Farber Cancer Institute (US), Rutgers Cancer Institute (US)

American College of Radiology Imaging Network, ECOG-ACRIN Cancer Research Group, National Institutes of Health, National Cancer Institute

Good health and well-being

Openalex Percentile: Top 74%

Prostate Cancer Treatment and Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Phase II Randomized Study of MK‐2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG‐ACRIN E2809) — B. Carthon, Ron Rodriguez, et al. · The Prostate (2026) | TGRS Research Map | TGRS